在心力衰竭患者群体中对代谢脆弱性指数的横截面评估
Kayode O Kuku1, Joseph J Shearer2, Jungnam Joo3
1Heart Disease Phenomics Laboratory, Epidemiology and Community Health Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
BMC cardiovascular disorders
|April 17, 2025
概括
代谢脆弱性指数 (MVX) 分数在临床试验和社区心力衰竭患者之间有所不同. 了解这些差异对于在不同患者群体中准确评估风险至关重要.
科学领域:
- 心脏病学 心脏病学
- 生物标志物研究 生物标志物研究
- 代谢学 代谢学 代谢学
背景情况:
- 代谢脆弱性指数 (MVX) 是一种使用NMR衍生措施的新型风险评分.
- MVX已经证明了心力衰竭患者死亡率的预测价值.
研究的目的:
- 评估MVX得分的分布和临床相关性.
- 在临床试验人群中比较MVX与与心力衰竭相匹配的社区队列,减少排气分数的缺血性心脏病患者.
主要方法:
- 将一项临床试验 (N=101) 与心力衰竭患者的社区队列 (N=288) 进行了比较.
- 使用NMR LipoProfile分析来计算性别特定的MVX得分.
- 使用回归模型来评估MVX和临床共变量之间的关系.
主要成果:
- 临床试验患者年轻,主要是男性,与队列相比,他们的MVX中位数得分较低.
- 在试验中,男性性别与较高的MVX相关;在队列中,NT-proBNP与MVX相关.
- 在多变量调整后,男性性别 (试验) 和NT-proBNP (队列) 仍然是MVX的显著相关物.
结论:
- 临床试验和社区心力衰竭队列之间的MVX分布和相关性存在显著差异.
- 这些发现影响了在不同研究环境中解释和应用MVX得分.
更多相关视频
06:04Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
732
09:40Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
Published on: January 19, 2017
11.6K
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
37
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
37
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K